OBJECTIVE: Minimally invasive approaches to mitral valve surgery are increasingly used, but the surgical approach must not compromise the clinical outcome for improved cosmesis. We examined the outcomes of mitral repair performed through right minithoracotomy or median sternotomy. METHODS: Between January 2002 and October 2011, 1011 isolated mitral valve repairs were performed in the University of Pennsylvania health system (455 sternotomies, 556 right minithoracotomies). To account for key differences in preoperative risk profiles, propensity scores identified 201 well-matched patient pairs with mitral regurgitation of any cause and 153 pairs with myxomatous disease. RESULTS: In-hospital mortality was similar between propensity-matched groups (0% vs 0% for the degenerative cohort; 0% vs 0.5%, P = .5 for the overall cohort; in minimally invasive and sternotomy groups, respectively). Incidence of stroke, infection, myocardial infarction, exploration for postoperative hemorrhage, renal failure, and atrial fibrillation also were comparable. Transfusion was less frequent in the minimally invasive groups (11.8% vs 20.3%, P = .04 for the degenerative cohort; 14.0% vs 22.9%, P = .03 for the overall cohort), but time to extubation and discharge was similar. A 99% repair rate was achieved in patients with myxomatous disease, and a minimally invasive approach did not significantly increase the likelihood of a failed repair resulting in mitral valve replacement. Patients undergoing minimally invasive mitral repair were more likely to have no residual post-repair mitral regurgitation (97.4% vs 92.1%, P = .04 for the degenerative cohort; 95.5% vs 89.6%, P = .02 for the overall cohort). In the overall matched cohort, early readmission rates were higher in patients undergoing sternotomies (12.6% vs 4.4%, P = .01). Over 9 years of follow-up, there was no significant difference in long-term survival between groups (P = .8). CONCLUSIONS: In appropriate patients with isolated mitral valve disease of any cause, a right minithoracotomy approach may be used without compromising clinical outcome.
OBJECTIVE: Minimally invasive approaches to mitral valve surgery are increasingly used, but the surgical approach must not compromise the clinical outcome for improved cosmesis. We examined the outcomes of mitral repair performed through right minithoracotomy or median sternotomy. METHODS: Between January 2002 and October 2011, 1011 isolated mitral valve repairs were performed in the University of Pennsylvania health system (455 sternotomies, 556 right minithoracotomies). To account for key differences in preoperative risk profiles, propensity scores identified 201 well-matched patient pairs with mitral regurgitation of any cause and 153 pairs with myxomatous disease. RESULTS: In-hospital mortality was similar between propensity-matched groups (0% vs 0% for the degenerative cohort; 0% vs 0.5%, P = .5 for the overall cohort; in minimally invasive and sternotomy groups, respectively). Incidence of stroke, infection, myocardial infarction, exploration for postoperative hemorrhage, renal failure, and atrial fibrillation also were comparable. Transfusion was less frequent in the minimally invasive groups (11.8% vs 20.3%, P = .04 for the degenerative cohort; 14.0% vs 22.9%, P = .03 for the overall cohort), but time to extubation and discharge was similar. A 99% repair rate was achieved in patients with myxomatous disease, and a minimally invasive approach did not significantly increase the likelihood of a failed repair resulting in mitral valve replacement. Patients undergoing minimally invasive mitral repair were more likely to have no residual post-repair mitral regurgitation (97.4% vs 92.1%, P = .04 for the degenerative cohort; 95.5% vs 89.6%, P = .02 for the overall cohort). In the overall matched cohort, early readmission rates were higher in patients undergoing sternotomies (12.6% vs 4.4%, P = .01). Over 9 years of follow-up, there was no significant difference in long-term survival between groups (P = .8). CONCLUSIONS: In appropriate patients with isolated mitral valve disease of any cause, a right minithoracotomy approach may be used without compromising clinical outcome.
Authors: Eugene A Grossi; Aubrey C Galloway; Angelo LaPietra; Greg H Ribakove; Patricia Ursomanno; Julie Delianides; Alfred T Culliford; Costas Bizekis; Rick A Esposito; F Gregory Baumann; Marc S Kanchuger; Stephen B Colvin Journal: Ann Thorac Surg Date: 2002-09 Impact factor: 4.330
Authors: Joerg Seeburger; Michael Andrew Borger; Volkmar Falk; Thomas Kuntze; Markus Czesla; Thomas Walther; Nicolas Doll; Friedrich Wilhelm Mohr Journal: Eur J Cardiothorac Surg Date: 2008-06-30 Impact factor: 4.191
Authors: Davy C H Cheng; Janet Martin; Avtar Lal; Anno Diegeler; Thierry A Folliguet; L Wiley Nifong; Patrick Perier; Ehud Raanani; J Michael Smith; Joerg Seeburger; Volkmar Falk Journal: Innovations (Phila) Date: 2011-03
Authors: Volkmar Falk; Davy C H Cheng; Janet Martin; Anno Diegeler; Thierry A Folliguet; L Wiley Nifong; Patrick Perier; Ehud Raanani; J Michael Smith; Joerg Seeburger Journal: Innovations (Phila) Date: 2011-03
Authors: Filip P Casselman; Sam Van Slycke; Helge Dom; Dave L Lambrechts; Yvette Vermeulen; Hugo Vanermen Journal: J Thorac Cardiovasc Surg Date: 2003-02 Impact factor: 5.209
Authors: R Scott McClure; Lawrence H Cohn; Esther Wiegerinck; Gregory S Couper; Sary F Aranki; R Morton Bolman; Michael J Davidson; Frederick Y Chen Journal: J Thorac Cardiovasc Surg Date: 2009-01 Impact factor: 5.209
Authors: Robert B Hawkins; J Hunter Mehaffey; Samuel M Kessel; Jolian J Dahl; Irving L Kron; John A Kern; Leora T Yarboro; Gorav Ailawadi Journal: J Thorac Cardiovasc Surg Date: 2018-04-03 Impact factor: 5.209
Authors: Andrew B Goldstone; William L Patrick; Jeffrey E Cohen; Chiaka N Aribeana; Rita Popat; Y Joseph Woo Journal: Ann Cardiothorac Surg Date: 2015-05